There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axcella Health (AXLA – Research Report) and Affimed (AFMD – Research Report) with bullish sentiments. Axcella Health (AXLA) Noble Financial analyst Robert LeBoyer maintained a Buy rating on Axcella Health today and set a price target of $6.00. The company's shares closed last Monday at $2.84, close to its 52-week low of $2.76. According to TipRanks.com, LeBoyer is a 5-star analyst with an average return of 40.5% and a 42.4% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and Ayala Pharmaceuticals. Axcella Health has an analyst consensus of Moderate Buy, with a price target consensus of $10.00. See today’s best-performing stocks on TipRanks >> Affimed (AFMD) Leerink Partners analyst Daina Graybosch maintained a Buy rating on Affimed today and set a price target of $12.00. The company's shares closed last Monday at $5.81. According to TipRanks.com, Graybosch is a 1-star analyst with an average return of -0.5% and a 37.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Bolt Biotherapeutics. Affimed has an analyst consensus of Moderate Buy, with a price target consensus of $12.00. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on AXLA: Quanterix’s AD Blood Test Gets Breakthrough Device Status; Shares Soar DocuSign: Bright Future, Better Entry Points Ahead What Do AST SpaceMobile’s Newly Added Risk Factors Tell Investors? Noble Financial Keeps a Buy Rating on Orion Group Holdings (ORN) Colliers Securities Believes Apyx Medical (APYX) Won’t Stop Here